조루 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 약제 유형별, 제형별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

The global premature ejaculation (PE) treatment market was valued at USD 2.95 billion in 2024 and is projected to reach USD 4.65 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.86%. This growth is attributed to advancements in treatments, fueled by a heightened awareness of sexual health issues. Premature ejaculation, one of the most common sexual dysfunctions in men, has led to an increasing demand for effective treatment options. As attitudes toward sexual health evolve, more individuals are seeking professional help for conditions like PE. This shift has expanded treatment options, including pharmaceuticals and behavioral therapies. Healthcare providers are introducing new, more effective treatments, including non-invasive therapies and oral medications, such as selective serotonin reuptake inhibitors (SSRIs) and local anesthetic creams. As awareness of available treatments increases, the market continues to experience consistent growth, driven by a demand for tailored solutions.

Key Market Drivers

Rising Pharmaceutical Innovation

Pharmaceutical companies are investing heavily in research and development to create medications specifically targeting premature ejaculation. For instance, dapoxetine, a selective serotonin reuptake inhibitor (SSRI), has been approved in multiple countries for PE treatment, offering targeted and effective options. These specialized medications have enhanced the efficacy of PE treatments, improving control over ejaculation timing and patient satisfaction. Ongoing developments in new medications aim to deliver better outcomes while reducing side effects, thereby improving patient compliance and comfort. Reducing side effects further enhances the appeal of treatments, as patients prefer therapies with minimal disruption to their daily lives.

Key Market Challenges

Side Effects and Safety Concerns

Certain pharmaceutical treatments for premature ejaculation, including SSRIs like dapoxetine, can cause side effects such as nausea, dizziness, headaches, and sexual side effects like reduced libido or erectile dysfunction. These side effects can reduce patient compliance and overall satisfaction. As medication responses vary from person to person, finding the most effective treatment can often involve a trial-and-error process, which can be frustrating for both patients and healthcare providers. Additionally, some individuals may have underlying health conditions or take medications that may interfere with PE treatments. Drug interactions are a concern, requiring healthcare providers to carefully assess potential risks. The long-term safety of certain treatments is not always well-established, and concerns about prolonged use may discourage some individuals from seeking or continuing treatment. Topical anesthetics, such as lidocaine creams, may also reduce sensation, affecting sexual pleasure for both partners.

Key Market Trends

Patient-Centric Approach

Healthcare providers are increasingly adopting patient-centric strategies by creating personalized treatment plans for individuals with PE. These plans take into account the severity of PE, underlying causes, medical history, and patient preferences. Patients are encouraged to actively participate in the decision-making process regarding their treatment options, leading to more collaborative and informed choices. The patient-centric approach emphasizes patient education and counseling, helping patients understand the condition, treatment options, potential side effects, and expected outcomes. Treatments may also include a holistic approach that addresses the physical, psychological, and emotional aspects of PE. Telemedicine and remote monitoring technologies are making it easier for patients to access care from home, enhancing convenience and accessibility while maintaining a patient-focused approach.

Key Market Players

• Absorption Pharmaceuticals Inc.
• Allergan PLC
• AstraZeneca PLC
• Bayer AG
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Innovus Pharmaceuticals Inc.
• Merck & Co., Inc.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.

Report Scope:

The Global Premature Ejaculation Treatment Market has been segmented as follows:

By Drug Type:

• Dapoxetine
• Phosphodiesterase Type 5 (PDE5) Inhibitors
• Selective Serotonin Reuptake Inhibitors
• Topical Anesthetics
• Zertane

By Treatment Type:

• Oral Therapies
• Topical Therapies

By Dosage Form:

• Pills
• Spray

By Distribution Channel:

• Hospitals
• Online Pharmacies
• Retail Pharmacies

By Region:

• North America: United States, Canada, Mexico
• Europe: France, United Kingdom, Italy, Germany, Spain
• Asia-Pacific: China, India, Japan, Australia, South Korea
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape

This section includes detailed company profiles of the major players in the Global Premature Ejaculation Treatment Market.

Available Customizations:

TechSci Research offers customization of the report to meet specific business needs, including the addition of up to five extra company profiles for further insights into the competitive landscape.

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Premature Ejaculation Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Dapoxetine, Phosphodiesterase Type 5 (PDE5) Inhibitors, Selective Serotonin Reuptake Inhibitors, Topical Anesthetics, Zertane)
  • 5.2.2. By Type (Oral Therapies, Topical Therapies)
  • 5.2.3. By Dosage Form (Pills, Spray)
  • 5.2.4. By Distribution Channel (Hospitals, Online Pharmacies, Retail Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Premature Ejaculation Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Type
  • 6.2.3. By Dosage Form
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Premature Ejaculation Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Dosage Form
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. India Premature Ejaculation Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Dosage Form
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Australia Premature Ejaculation Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Dosage Form
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Japan Premature Ejaculation Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Type
      • 6.3.4.2.2. By Type
      • 6.3.4.2.3. By Dosage Form
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. South Korea Premature Ejaculation Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Type
      • 6.3.5.2.2. By Type
      • 6.3.5.2.3. By Dosage Form
      • 6.3.5.2.4. By Distribution Channel

7. Europe Premature Ejaculation Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Type
  • 7.2.3. By Dosage Form
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Premature Ejaculation Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Dosage Form
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Germany Premature Ejaculation Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Dosage Form
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Spain Premature Ejaculation Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Dosage Form
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Premature Ejaculation Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Dosage Form
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. United Kingdom Premature Ejaculation Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Dosage Form
      • 7.3.5.2.4. By Distribution Channel

8. North America Premature Ejaculation Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Type
  • 8.2.3. By Dosage Form
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Premature Ejaculation Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Dosage Form
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Mexico Premature Ejaculation Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Dosage Form
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Canada Premature Ejaculation Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Dosage Form
      • 8.3.3.2.4. By Distribution Channel

9. South America Premature Ejaculation Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Type
  • 9.2.3. By Dosage Form
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Premature Ejaculation Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Dosage Form
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Premature Ejaculation Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Dosage Form
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Premature Ejaculation Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Dosage Form
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Premature Ejaculation Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Type
  • 10.2.3. By Dosage Form
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Premature Ejaculation Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Dosage Form
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Premature Ejaculation Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Premature Ejaculation Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Dosage Form
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Premature Ejaculation Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Absorption Pharmaceuticals Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Allergan PLC
• 16.3. AstraZeneca PLC
• 16.4. Bayer AG
• 16.5. Eli Lilly and Company
• 16.6. GlaxoSmithKline PLC
• 16.7. Innovus Pharmaceuticals Inc.
• 16.8. Merck & Co., Inc.
• 16.9. Pfizer, Inc.
• 16.10.Teva Pharmaceutical Industries Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer